Puma Biotechnology, Inc.
PBYIAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| TD Cowen | maintain | Hold | Aug 7, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 2, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 4, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 3, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 20, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 31, 2022 |
| HC Wainwright & Co. | maintain | Buy | Aug 5, 2022 |
| HC Wainwright & Co. | maintain | Buy | May 6, 2022 |
| Citigroup | upgrade | Neutral →Buy | Sep 28, 2021 |
| Goldman Sachs | maintain | Sell | Aug 6, 2021 |
| RBC Capital | maintain | Sector Perform | Aug 6, 2021 |
| Citigroup | maintain | Neutral | Aug 10, 2020 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $0.23| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $0.15 | $0.09 | $55.1M | $57.5M |
| Aug 6, 2026 | $0.19 | $0.04 | $56.5M | $53.0M |
| May 7, 2026 | $-0.04 | $-0.13 | $44.8M | $42.0M |
| Feb 26, 2026 | $0.29 | $0.24 | $59.9M | $68.6M |
| Nov 6, 2025 | $0.21 | $0.09 | $51.9M | $51.0M |
| Aug 7, 2025 | $0.15 | $0.11 | $49.2M | $52.0M |
| May 8, 2025 | $0.10 | $0.02 | $43.1M | $44.5M |
| Feb 27, 2025 | $0.43 | $0.10 | $59.1M | $52.5M |
News
Puma's U.S. NERLYNX demand is heading toward a second year of growth, yet China royalties are shrinking, a split the company must balance.
Puma Biotechnology, Inc. (PBYI) Q3 2026 Earnings Call Prepared Remarks Transcript
Puma Biotechnology NASDAQ: PBYI reported third-quarter 2026 revenue of $55.1 million and raised its full-year net income forecast, even as it lowered its outlook for royalties and narrowed its sales guidance for breast cancer drug NERLYNX.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced its third quarter earnings on Nov. 5 and followed with a conference call to provide a corporate update.
LOS ANGELES--(BUSINESS WIRE)--Puma biotechnology reported that it granted inducement awards in October 2026, as required under Nasdaq Listing Rule 5635(c)(4).
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its third quarter 2026 results and host a conference call on Thursday, November 5, 2026, after the close.
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Puma Biotechnology (NASDAQ: PBYI - Get Free Report) and TG Therapeutics (NASDAQ: TGTX - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Institutional and Insider Ownership 61.3% of Puma Biotechnology
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.
LOS ANGELES--(BUSINESS WIRE)--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.
NERLYNX gives PBYI an established revenue stream that can support alisertib's development into a potential second oncology franchise. Currently, PBYI already has positive cash flows and a healthy balance sheet, which I believe should give them flexibility as their R&D progresses. Alisertib's biomarker strategy could identify responsive patients, but bear in mind that it's still a speculative asset in Phase 2 trials.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).
BlackRock Inc. bought a new stake in Puma Biotechnology, Inc. (NASDAQ: PBYI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 3,804,736 shares of the biopharmaceutical company's stock, valued at approximately $30,856,000. BlackRock Inc. owned 7.47% of
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.